| Medical and Health Sciences | Lifetime | 92 | BE 3 | 100.00 |
| Medical and Health Sciences | 2021-2025 | 135 | BE 1 | 99.97 |
| Oncology | Lifetime | 2 | BE 1 | 99.99 |
| Pulmonary and Respiratory Medicine | Lifetime | 27 | BE 1 | 99.96 |
| Pathology and Forensic Medicine | Lifetime | 166 | BE 1 | 99.34 |
| Surgery | Lifetime | 635 | BE 9 | 99.40 |
| Hepatology | Lifetime | 322 | BE 4 | 97.38 |
| Cancer Research | Lifetime | 566 | BE 12 | 96.33 |
| Gastroenterology | Lifetime | 365 | BE 10 | 94.19 |
| Oncology | 2021-2025 | 11 | BE 1 | 99.93 |
| Pulmonary and Respiratory Medicine | 2021-2025 | 37 | BE 1 | 99.85 |
| Surgery | 2021-2025 | 239 | BE 8 | 98.53 |
| Pathology and Forensic Medicine | 2021-2025 | 145 | BE 2 | 96.36 |
| Gastric Cancer Management and Outcomes | Lifetime | 1 | BE 1 | 99.99 |
| Colorectal Cancer Treatments and Studies | Lifetime | 1 | BE 1 | 99.99 |
| Cancer Treatment and Pharmacology | Lifetime | 3 | BE 1 | 99.97 |
| Genetic factors in colorectal cancer | Lifetime | 3 | BE 1 | 99.95 |
| Colorectal and Anal Carcinomas | Lifetime | 4 | BE 1 | 99.91 |
| Hepatocellular Carcinoma Treatment and Prognosis | Lifetime | 19 | BE 1 | 99.88 |
| Pancreatic and Hepatic Oncology Research | Lifetime | 25 | BE 1 | 99.89 |
| Gastrointestinal Tumor Research and Treatment | Lifetime | 18 | BE 1 | 99.81 |
| Lung Cancer Treatments and Mutations | Lifetime | 47 | BE 1 | 99.83 |
| Colorectal Cancer Surgical Treatments | Lifetime | 31 | BE 1 | 99.74 |
| Cancer Genomics and Diagnostics | Lifetime | 89 | BE 2 | 99.75 |
| Esophageal Cancer Research and Treatment | Lifetime | 37 | BE 1 | 99.63 |
| Cancer Immunotherapy and Biomarkers | Lifetime | 151 | BE 1 | 99.60 |
| Metastasis and carcinoma case studies | Lifetime | 50 | BE 1 | 99.20 |
| Neuroendocrine Tumor Research Advances | Lifetime | 92 | BE 1 | 99.51 |
| Cholangiocarcinoma and Gallbladder Cancer Studies | Lifetime | 84 | BE 1 | 99.50 |
| HER2/EGFR in Cancer Research | Lifetime | 126 | BE 3 | 99.41 |
| Radiomics and Machine Learning in Medical Imaging | Lifetime | 403 | BE 4 | 98.68 |
| Neuroblastoma Research and Treatments | Lifetime | 271 | BE 3 | 98.40 |
| Lung Cancer Research Studies | Lifetime | 474 | BE 7 | 98.23 |
| Cancer Research and Treatments | Lifetime | 506 | BE 3 | 97.39 |
| Colorectal Cancer Screening and Detection | Lifetime | 665 | BE 2 | 97.66 |
| Renal cell carcinoma treatment | Lifetime | 660 | BE 6 | 97.40 |
| Melanoma and MAPK Pathways | Lifetime | 324 | BE 4 | 96.59 |
| Fibroblast Growth Factor Research | Lifetime | 347 | BE 2 | 95.26 |
| Advanced Breast Cancer Therapies | Lifetime | 652 | BE 15 | 94.83 |
| Neutropenia and Cancer Infections | Lifetime | 941 | BE 13 | 93.02 |
| Vascular Anomalies and Treatments | Lifetime | 468 | BE 9 | 89.98 |
| Chemotherapy-related skin toxicity | Lifetime | 843 | BE 13 | 81.05 |
| Gastric Cancer Management and Outcomes | 2021-2025 | 3 | BE 1 | 99.95 |
| Colorectal Cancer Treatments and Studies | 2021-2025 | 3 | BE 1 | 99.92 |
| Esophageal Cancer Research and Treatment | 2021-2025 | 6 | BE 1 | 99.77 |
| Pancreatic and Hepatic Oncology Research | 2021-2025 | 15 | BE 1 | 99.66 |
| Genetic factors in colorectal cancer | 2021-2025 | 11 | BE 1 | 99.64 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 97 | BE 1 | 99.61 |
| Gastrointestinal Tumor Research and Treatment | 2021-2025 | 23 | BE 1 | 99.12 |
| Cancer Genomics and Diagnostics | 2021-2025 | 119 | BE 1 | 99.01 |
| Cancer Treatment and Pharmacology | 2021-2025 | 49 | BE 1 | 98.95 |
| Lung Cancer Treatments and Mutations | 2021-2025 | 244 | BE 1 | 98.40 |
| Neuroendocrine Tumor Research Advances | 2021-2025 | 161 | BE 2 | 96.10 |
| HER2/EGFR in Cancer Research | 2021-2025 | 238 | BE 8 | 96.29 |
| Melanoma and MAPK Pathways | 2021-2025 | 125 | BE 2 | 93.36 |
| Colorectal and Anal Carcinomas | 2021-2025 | 399 | BE 3 | 90.76 |
| Fibroblast Growth Factor Research | 2021-2025 | 121 | BE 1 | 86.28 |
| Neuroblastoma Research and Treatments | 2021-2025 | 465 | BE 2 | 88.85 |
| Metastasis and carcinoma case studies | 2021-2025 | 588 | BE 3 | 82.64 |
| Multiple and Secondary Primary Cancers | 2021-2025 | 770 | BE 6 | 70.48 |
| Barrier Structure and Function Studies | 2021-2025 | 376 | BE 1 | 65.60 |
| Biochemical and Molecular Research | 2021-2025 | 856 | BE 12 | 63.15 |